Skip to content

Human Chorionic Gonadotropin (hCG) Priming Prior to Controlled Ovarian Hyperstimulation (COH) in Poor Responder In Vitro Fertilization (IVF) Patients

hCG Priming Prior to COH in Poor Responder IVF Patients

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00870025
Acronym
APPE
Enrollment
60
Registered
2009-03-26
Start date
2008-10-31
Completion date
2010-09-30
Last updated
2015-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Response

Keywords

androgens, hCG, low response, IVF, Ovarian response in women with previous low response

Brief summary

There is a decline in androgen concentration with ovarian aging. Also, ovarian response to COH in IVF cycles diminishes with ovarian aging. Recent evidence suggest that testosterone or DHEA may improve ovarian response in poor prognosis patients by increasing intraovarian androgen concentration. A physiological way to induce androgen synthesis within the ovary is to stimulate theca cells androgen production by hCG stimulation. By doing this in the previous cycle we might expect a better response to COH.

Interventions

BIOLOGICALhuman chorionic gonadotropin

200 IU, sc, every 5 days, 4 doses

BIOLOGICALplacebo

diluent, every 5 days, s.c., 4 doses

Sponsors

IVI Madrid
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 41 Years
Healthy volunteers
No

Inclusion criteria

* previous IVF cycle with 5 or less mature follicles or 5 or less oocyte retrieved

Exclusion criteria

* 42 years or older * BMI \<18 or \>30

Design outcomes

Primary

MeasureTime frame
pregnancy rate2 weeks after intervention

Secondary

MeasureTime frame
number of oocytes retrieved2 weeks after intervention

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026